Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D)

NCT ID: NCT05082012

Last Updated: 2024-06-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 123 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-17
• Study Completion Date: 2024-05-09

Brief Summary

Prospective, multicenter, unblinded study to evaluate outcomes of the Lapiplasty® Procedure using the Lapiplasty® Mini-Incision™ System for patients in need of hallux valgus surgery.

Up to 200 subjects will be treated in this study at up to 20 clinical sites. Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Detailed Description

Prospective, multicenter, unblinded study to evaluate outcomes of the Lapiplasty® Procedure using the Lapiplasty® Mini-Incision™ System for patients in need of hallux valgus surgery:

1. To determine radiographic recurrence of hallux valgus and the timing of failure following hallux valgus correction with the Lapiplasty® Procedure.

2. To determine whether the Lapiplasty® Procedure effectively corrects anatomical alignment of the 1st metatarsal and sesamoids in all three planes.

3. To assess whether early weight-bearing after the Lapiplasty® Procedure affects the union rates or causes loss of 3-plane correction.

4. To evaluate the quality of life and pain scores following the Lapiplasty® Procedure.

Conditions

Hallux Valgus; Bunion

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Treatment of Hallux Valgus

Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.

Intervention Type: DEVICE

Other Intervention Names

Lapiplasty® Mini-Incision™ Procedure

Eligibility Criteria

Inclusion Criteria

Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:

1. Male and females between the ages 14 and 58 years at the time of consent;

2. Closed physeal plates at the time of consent;

3. Intermetatarsal angle is between 10.0˚ - 22.0˚;

4. Hallux valgus angle is between 16.0˚ - 40.0˚;

5. Willing and able to adhere to early weight-bearing instructions post-operatively;

6. Capable of completing self-administered questionnaires;

7. Acceptable surgical candidate, including use of general anesthesia;

8. Female patients must be of non-child bearing potential or have a negative pregnancy test within 7 days prior to index procedure;

9. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits;

10. Willing and able to provide written informed consent.

Exclusion Criteria

Patients satisfying the following criteria will not be eligible for participation:

1. Previous surgery for hallux valgus on operative side;

2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe or lesser toes/digits);

3. Additional concomitant procedures outside of the 1st ray;

4. Moderate or Severe osteoarthritis of the MTP joint based on radiographic imaging (including lack of evident crista) or positive grind test;

5. Symptomatic flatfoot or asymptomatic flatfoot (defined as calcaneal inclination <5˚and talonavicular subluxation/uncovering >50%);

6. BMI >40 kg/m²;

7. Current nicotine user, including current use of nicotine patch;

8. Current clinical diagnosis of diabetes with fasting plasma glucose > 126 mg/dL and/or HbA1c ≥7.0;

9. Current clinical diagnosis of peripheral neuropathy or by assessment on 4-point monofilament test;

10. Current clinical diagnosis of fibromyalgia;

11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD);

12. Current uncontrolled hypothyroidism;

13. Previously sensitized to titanium;

14. Currently taking oral steroids or rheumatoid biologics;

15. Currently taking immunosuppressant drugs;

16. Insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease;

17. Active, suspected or latent infection in the affected area;

18. Use of synthetic or allogenic bone graft substitutes;

19. Current diagnosis of metatarsus adductus (defined as MAA ≥ 23˚);

20. Known keloid and hypertrophic scar forming;

21. Scheduled to undergo a same-day bilateral procedure. Patient agrees to refrain from the Lapiplasty® Procedure (or other hallux valgus procedures) on contralateral foot for minimum of 6 months post index procedure;

22. Patient has previously been enrolled into this study for a contralateral procedure;

23. Scheduled for any concomitant procedure that would alter patient's ability to early weight-bear post-procedure;

24. Patient requires an incision >4.0 cm to complete the procedure (determined pre-operatively or intra-operatively);

25. Patient is actively involved with a workman's compensation case or is currently involved in litigation;

26. Patient is currently or has participated in a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in the Treace ALIGN3D™ study without ongoing protocol defined AE; these are not exclusionary;

27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 58 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Treace Medical Concepts, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jody McAleer, DPM, FACFAS

Role: PRINCIPAL_INVESTIGATOR

JCMG - Podiatry

Locations

DOC - Decatur Orthopaedic Clinic

Decatur, Alabama, United States

DOC - Decatur Orthopaedic Clinic

Hartselle, Alabama, United States

Phoenix Foot and Ankle Institute

Scottsdale, Arizona, United States

Orlando Foot and Ankle Clinic - Waterford Lakes Office

Orlando, Florida, United States

JCMG - Podiatry

Jefferson City, Missouri, United States

Desert Orthopaedic Center

Las Vegas, Nevada, United States

University of Pennsylvania / Penn Medicine

Philadelphia, Pennsylvania, United States

Stonebriar Foot and Ankle

Frisco, Texas, United States

Foot & Ankle Associates of North Texas - Keller

Keller, Texas, United States

Sports Medicine Associates of San Antonio

San Antonio, Texas, United States

Countries

United States

Other Identifiers

CP2021-1

Identifier Type: -

Identifier Source: org_study_id